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Background: To assess the impact of a continuous measure of adherence with infliximab main-
tenance treatment in Crohn’s disease (CD) during the first year of treatment on CD-related health 
care utilization, CD-related hospitalizations, inpatient costs, and length of hospital stay.
Patients and methods: A retrospective claims analysis using the IMS LifeLink Health Plan 
Claims Database (September 1, 2004, to June 30, 2009) was conducted. Continuous enrollment 
for 12 months before and 12 months after the index date was required. Patients were required to 
have at least two claims with an International Classification of Diseases, 9th Revision, Clinical 
Modification diagnosis code for CD (555.xx) pre-index and be aged $ 18 years at index. Patients 
with three infusions during the first 56 days post-index and at least one infusion following day 
56 post-index were considered to have maintenance therapy. Adherence and nonadherence were 
defined as a medication possession ratio of $ 80% and , 80%, respectively.
Results: Four hundred forty-eight patients were included in the analysis (mean age, 42.6 
years; 56% female; mean ± standard deviation [SD] and median number of infliximab infu-
sions, 7.35 ± 1.60 and 8). The number of patients who met the definition of adherence was 344 
(77%). CD-related health care utilization was not significantly impacted by adherence except 
for ancillary services and radiology. Fewer adherent patients were hospitalized compared with 
nonadherent patients (9% versus 16%; P = 0.03). Adherent patients had fewer mean ± SD 
and median days in the hospital (5.5 ± 3.4 and 5 days) compared with nonadherent patients 
(13.1 ± 14.2 and 8 days; P = 0.01). Mean ± SD and median hospital costs were significantly 
greater for nonadherent patients ($40,822 ± $49,238 and $28,864) compared with adherent 
patients ($13,704 ± $10,816 and $9938; P = 0.002).
Conclusion: Adherence with maintenance infliximab over 12 months was associated with lower 
rates of CD-related hospitalizations and inpatient costs and a shorter length of hospital stay.
Keywords: costs, Crohn’s disease, hospitalization, infliximab, length of stay, medication 
adherence
Introduction
Crohn’s disease (CD) is an idiopathic and chronic inflammatory bowel disease that 
affects approximately 144–198 per 100,000 people in North America.1 It is charac-
terized by episodes of acute symptomatic inflammation of the gut (exacerbations) 
alternating with periods of reduced disease activity (remission). CD significantly 
impacts patients’ health-related quality of life, having deleterious effects on their 
physical, social, and emotional well-being.2–5 Because there is no known cure for the 
disease, patients with CD – especially younger patients with early-onset disease – may 
expect years of medical care, hospitalization, and surgery.3,4 Total CD-related treat-
ment costs in the United States (US) using 2003–2004 estimates were $3.6 billion.6 
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Hospitalization and outpatient costs for this time period were 
31.4% and 33.3% of total CD-related costs, respectively.6 
Using more recent 2006 estimates, the total economic bur-
den (direct medical and indirect costs) of CD in the US was 
$10.9–$15.5 billion.7
A variety of therapeutic agents, including 5-amino-
salicylates, systemic corticosteroids, immunomodulators 
(eg,   6-mercaptopurine, azathioprine, and methotrexate), 
antibiotics, and biologic agents, have been used in the treat-
ment of CD in an attempt to induce and maintain clinical 
remission.5 The advent of biologic agents in CD treatment 
has dramatically affected treatment expectations in these 
patients. 
Infliximab is a chimeric immunoglobulin G1 monoclonal 
antibody biologic against tumor necrosis factor-α (TNF-α). 
TNF-α has been implicated in stimulating an inappropriate 
inflammatory gastrointestinal tract response, resulting in 
diarrhea, fever, abdominal pain, and weight loss associated 
with CD.8   Infliximab has proven to be efficacious in inducing 
and maintaining clinical remission and mucosal healing in 
adult and pediatric (aged $ 6 years) patients with moderate-
to-severe CD and adult patients with fistulizing CD.9–12
One of the goals of CD treatment is to maintain remission 
in order to prevent exacerbations that require costly hospital-
izations and surgeries.13 Infliximab has been shown to reduce 
hospitalizations, surgeries, and procedures, especially when 
the drug is prescribed as a scheduled maintenance versus 
periodic treatment regimen.14–19
Adherence to a treatment regimen in a chronic condi-
tion such as CD is critical for improving patient outcomes 
over the long term; however, few studies have evaluated 
the effect of a continuous measure of adherence with bio-
logic agents on health care services utilization, outcomes, 
and costs in inflammatory bowel disease. The objective 
of the current study was to assess the observed impact of 
adherence with infliximab maintenance treatment in CD 
during the first year of treatment on CD-related health care 
utilization, hospitalizations, inpatient costs, and length of 
hospital stay.
Patients and methods
Data source
A retrospective, observational cohort was obtained for this 
analysis using medical and pharmacy claims data from 
the IMS LifeLink Health Plan Claims Database dated 
from   September 1, 2004, to June 30, 2009. The IMS Life-
Link Database comprises fully adjudicated medical and 
pharmaceutical claims for over 60 million patients from 
over 90 health plans across the US.20 The database content 
includes hospital admission and discharge dates, dates of 
service, procedure codes, patient demographics (eg, age, 
sex), length of hospital stay, medical services and drug costs, 
and drug information (eg, drug name, dose, strength, days’ 
supply and quantity dispensed, date of service).
Sample selection
Patients were included in this study if all of the following 
inclusion criteria were met: the patient had at least one medi-
cal claim for infliximab (the date of service on the first claim 
defined the index date); the patient had at least two diagno-
ses of CD as defined by the International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) 
code of 555.xx during the 12-month pre-index period; there 
was no evidence of infliximab use during the 6-month pre-
index period; the patient was aged $ 18 years at the index 
date; and the patient was continuously enrolled in the health 
plan for at least 12 months before and 12 months after the 
index date.
Patients were excluded from the study if any of the follow-
ing occurred: the patient was not continuously enrolled in the 
health plan for at least 12 months before and 12 months after 
the index date; the patient had at least one medical claim with 
an ICD-9-CM code for psoriasis (696.1), rheumatoid arthri-
tis (714.xx), psoriatic arthritis (696.0), or ankylosing spon-
dylitis (720.xx) during the pre-index period; or the patient had 
pharmacy National Drug Code claims for infliximab. Patients 
with a pharmacy National Drug Code claim for infliximab 
were excluded to focus results on the population of patients 
receiving all infliximab infusions from health care profes-
sionals submitting medical claims. Continuity in the type of 
claim used for infliximab billing purposes (ie, medical versus 
pharmacy) ensured that any observed gaps in therapy were 
not due to administrative errors consequential to changes in 
the type of claim used. Additionally, the date of service on 
an infliximab medical claim is representative of the date of 
actual infusion, whereas the date of service on an infliximab 
pharmacy claim is representative of when the drug claim was 
adjudicated by a pharmacy. The index date was defined as 
the first claim for infliximab received between September 1, 
2005, and June 30, 2008.
Definitions and measures
The continuous measure of adherence was defined as a 
medication possession ratio (MPR) for patients receiving 
infliximab maintenance treatment. Patients were considered 
to have received infliximab maintenance treatment if they 
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received three infusions during the first 56 days post-index 
and one or more infusions following day 56 during the 
12-month post-index period. The MPR was calculated as 
the total days’ supply of infliximab administered during the 
12-month post-index period divided by 360.
CD-related utilization of health care services, hospitaliza-
tion rate, length of hospital stay (days), and inpatient costs 
were compared between maintenance infliximab-treated 
patients with adherence (MPR $ 80%) and patients without 
adherence (MPR , 80%).21,22 A claim was considered CD-
related if an ICD-9-CM diagnosis code of CD was present in 
any position on the claim. A hospitalization was considered 
CD-related if an ICD-9-CM diagnosis of CD was present in 
any position on the discharge record. In the IMS LifeLink 
Database, temporal positioning of the ICD-9-CM diagnosis 
on the discharge record (eg, first, second, third) is not relevant 
for determination of reason for hospitalization. Presence of 
a diagnosis code in any position on the discharge record is 
indicative of a disease-related hospitalization.
Statistical analyses
Baseline characteristics between the adherent cohort and 
nonadherent cohort were compared. Chi-square and t-test/
nonparametric Wilcoxon tests were used to test the statistical 
significance of nominal and continuous variables, respectively. 
Health care resource utilization and costs were analyzed and 
compared descriptively between the two adherence cohorts. 
Statistical significance was defined by a P value # 0.05.
Results
The final sample consisted of 448 patients who met the inclu-
sion criteria (Table 1), 344 (77%) of whom had an MPR $ 80% 
and were included in the adherence cohort, while the remaining 
104 (23%) patients did not meet adherence (ie, MPR , 80%). 
The baseline characteristics were similar between the adher-
ent and nonadherent cohorts (Table 2). The mean ± standard 
deviation (SD) age of the total population (n = 448) was 
42.6 ± 14.8 years, and the majority (56%) of patients were 
female. The mean ± SD and median number of infliximab 
infusions during the 12-month post-index period in the total 
population was 7.35 ± 1.60 and 8, respectively.
Pre-infliximab CD-related utilization
When looking at the 12 months prior to the first inflix-
imab infusion, use of pharmacy (immunomodulators, 
5-amino  salicylates, corticosteroids, other biologics, and 
other pharmacy services) and outpatient services was simi-
lar between the adherent and nonadherent cohorts, except 
for emergency room visits and ancillary/other outpatient 
services (Table 3). A statistically significant difference 
in the percentage of patients with at least one emergency 
room visit claim was observed between the adherent and 
nonadherent cohorts (12% versus 21%; P = 0.02) for the 
12 months pre-index. The median number of claims for 
ancillary/other outpatient services among patients with 
at least one claim was significantly higher in the adherent 
cohort than in the   nonadherent cohort (4 versus 3, P = 0.02) 
prior to   infliximab exposure. No significant differences were 
found in the proportion of patients with a hospitalization, 
length of hospital stay, or inpatient costs (Table 3).
Post-infliximab CD-related utilization
Utilization of CD-related health care services during the 
12 months post-index is presented in Table 4. The mean ± SD 
Table 1 Attrition of infliximab study population, by reason
Patients excluded Patients remaining
n % n %
Total number of patients before any attrition 18,500 100.0
Less than 18 years of age 609 3.3 17,891 96.7
Not enrolled for 360 days pre-index 7631 41.2 10,260 55.5
Not enrolled for 360 days post-index 2115 11.4 8145 44.0
no evidence ($ 2 claim days) of pre-index CD 5971 32.3 2174 11.8
Has claim for an exclusionary comorbidity in 360 days pre-index 208 1.1 1966 10.6
Has infliximab claim in 180 days pre-index 782 4.2 1184 6.4
Has colectomy within 84 days post-index 27 0.1 1157 6.3
Has infliximab NDC claim post-index 66 0.4 1091 5.9
Has non-index biologic post-index 78 0.4 1013 5.5
Data quality issue 16 0.1 997 5.4
Does not have three induction infusions 513 2.8 484 2.6
Does not have maintenance infusions 36 0.2 448 2.4
Patients available for analysis 448 2.4
Abbreviations: CD, Crohn’s disease; nDC, national Drug Code.
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Table 2 Demographic characteristics by cohort
Characteristic Total,  
n = 448
Adherent cohort  
(MPR $ 80%),  
n = 344
Nonadherent cohort  
(MPR , 80%),  
n = 104
P value
Age, years
  Mean (SD)
  Median
42.6 (14.8)
43
42.4 (14.9)
42
43.3 (14.2)
45
 
0.48
Sex, n (%)
  Female
  Male
251 (56)
197 (44)
199 (58)
145 (42)
52 (50)
52 (50)
 
0.16
Payer type, n (%) n/A
  Commercial plan
  Medicaid
  Medicare risk
  Self-insured
424 (95)
2 (,1)
10 (2)
12 (3)
325 (94)
1 (,1)
10 (3)
8 (2)
99 (95)
1 (1)
0 (0)
4 (4)
Region, n (%) 0.33
  northeast
  Midwest
  South
  West
69 (15)
187 (42)
132 (29)
60 (13)
48 (14)
149 (43)
103 (30)
44 (13)
21 (20)
38 (37)
29 (28)
16 (15)
First infliximab infusion place of service, n (%) n/A
  Outpatient office
  Outpatient hospital
  Inpatient hospital
  Unknown
  All other POS codes
295 (66)
60 (13)
48 (11)
30 (7)
15 (3)
234 (68)
45 (13)
34 (10)
22 (6)
9 (3)
61 (59)
15 (14)
14 (13)
8 (8)
6 (6)
Abbreviations: MPR, medication possession ratio; n/A, not applicable; POS, place of service; SD, standard deviation.
  number of infliximab pharmacy claims was significantly 
greater in patients with adherence than those without 
(8.1 ± 0.9 versus 5.0 ± 1.0; P , 0.001). There were no 
statistically significant differences in utilization of specific 
CD-related pharmacy services (ie, immunomodulators, 
5-aminosalicylates, corticosteroids, and other pharmacy 
  services) during the post-index period. The median number of 
ancillary and other outpatient services claims among patients 
with at least one claim was significantly greater in the adherent 
cohort compared with the nonadherent cohort (22 versus 18; 
P , 0.001); however, adherent patients with at least one radiol-
ogy claim had fewer median radiology claims compared with 
nonadherent patients (2 versus 3; P = 0.004).
Post-index CD-related hospitalizations, length of hospital 
stay, and inpatient costs are reported in Table 5. A lower 
proportion of patients in the adherent cohort was hospitalized 
than in the nonadherent cohort (9% versus 16%, P = 0.03). 
Among all patients, the mean ± SD number of hospitaliza-
tions was lower in those with adherence than in those without 
(0.10 ± 0.36 versus 0.21 ± 0.52), as were inpatient costs 
($1235 ± 5067 versus $6673 ± 24,631).
Among the subset of patients with at least one hospital-
ization, patients demonstrating adherence to infliximab had 
significantly shorter median length of hospital stay compared 
with those without adherence (5 versus 8 days; P = 0.01). 
Patients with adherence also trended toward fewer mean ± SD   
hospitalizations than patients without   adherence, although 
the difference was not statistically significant (1.2 ± 0.5 
  versus 1.3 ± 0.5). Mean ± SD inpatient costs, however, 
were significantly lower for the adherent cohort than 
for the nonadherent cohort ($13,704 ± 10,816 versus 
$40,822 ± 49,238; P = 0.002). Median costs are presented 
in Figure 1.
Discussion
Nonadherence with treatment regimens in chronic diseases 
is a ubiquitous problem. Nonadherence with oral therapies 
in gastrointestinal disease and its subsequent impact on 
medical costs is well documented.23–35 Reported nonad-
herence rates for oral medications in inflammatory bowel 
disease range between 7% and 72%, with most studies 
reporting nonadherence rates between 30% and 45%.28 Few 
studies, however, have evaluated the impact of adherence 
on biologic therapies in inflammatory bowel disease, and 
even fewer studies have focused on the impact of adherence 
with maintenance therapy specifically in patients with CD. 
To our knowledge, as of the date of this publication, this is 
the first study to evaluate the impact of a continuous mea-
sure of adherence with infliximab maintenance therapy, as 
measured by MPRs over 12 months, in CD treatment.
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Table 3 Pre-index utilization of CD-related health care services
Services Adherent cohort 
(MPR $ 80%),  
n = 344
Nonadherent  
cohort  
(MPR , 80%),  
n = 104
P value
Pharmacy services
Immunomodulators
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
5-aminosalicylates
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Corticosteroids
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Other pharmacy services
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
179 (52)
4.87 (3.61)
4
184 (53)
5.22 (3.61)
4
214 (62)
3.63 (2.73)
3
68 (20)
2.76 (3.22)
2
53 (51)
4.32 (3.46)
3
50 (48)
4.82 (3.06)
4
57 (55)
3.77 (2.52)
4
13 (13)
3.31 (2.75)
3
0.85
0.32
0.33
0.70
0.18
0.54
0.09
0.20
Outpatient services
Emergency room visits
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Laboratory and pathology
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Radiology
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Physician office visits
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Surgical services
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Ancillary/all other outpatient services
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
41 (12)
1.44 (0.95)
1
287 (83)
12.22 (13.65)
9
173 (50)
2.64 (1.94)
2
309 (90)
4.75 (3.45)
4
158 (46)
1.51 (0.94)
1
263 (76)
6.33 (6.88)
4
22 (21)
1.41 (0.67)
1
93 (89)
11.90 (10.60)
10
53 (51)
2.30 (1.56)
2
92 (88)
5.57 (4.38)
5
48 (46)
1.33 (0.91)
1
77 (74)
5.22 (7.63)
3
0.02
0.63
0.14
0.67
0.91
0.36
0.69
0.07
0.97
0.06
0.61
0.02
Inpatient services
Patients with at least one hospitalization, n (%) 74 (22) 21 (20) 0.77
(Continued)
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Table 3 (Continued)
Services Adherent cohort 
(MPR $ 80%),  
n = 344
Nonadherent  
cohort  
(MPR , 80%),  
n = 104
P value
Number of hospitalizations
  Mean (SD)
  Median
number of hospital days
  Mean (SD)
  Median
Hospitalization costs, $
  Mean (SD)
  Median
1.22 (0.50)
1
7.80 (7.26)
6
16,966 (18,286)
10,178
1.14 (0.48)
1
6.38 (4.04)
5
12,046 (8617)
8462
0.41
0.48
0.32
Abbreviations: CD, Crohn’s disease; MPR, medication possession ratio; SD, standard deviation.
In the current study, 23% of patients with CD met the cri-
teria for nonadherence with infliximab maintenance therapy 
at 12 months. Kane et al29 reported a higher nonadherence 
rate of 34% with maintenance infliximab treatment over 
12 months in a retrospective study of patients with CD from 
the Integrated Health Care Information Service claims data-
base. That study, however, did not evaluate adherence using 
MPR; adherence was measured by the number of infusions 
administered over one year. The adherence rate of 77% in the 
current study is more consistent with the adherence rate of 
70%–80% with TNF-α inhibitors in patients with rheumatoid 
arthritis over 12 months, as reported by Tang et al.30
Medication adherence, as defined by the International 
Society for Pharmacoeconomics and Outcomes Research, 
is the “extent to which a patient acts in accordance with the 
prescribed interval and dose of a dosing regimen.”36 As per 
the methodological standards of the International Society for 
Pharmacoeconomics and Outcomes Research, medication 
adherence may be estimated by an MPR calculation; however, 
unlike oral or patient self-administered medications, intrave-
nous medications administered by health care professionals 
(versus patients) may have a greater degree of physician input 
and control on the prescribed interval and dose. This poses a 
challenge to patient adherence research for a treatment like 
infliximab yet offers a view on overall adherence compared 
with prescribing recommendations; this adherence estimate 
is the result of treatment-related shared decision-making 
between the patient and health care professional.
The most notable finding in this study is the economic 
impact of adherence with maintenance infliximab on hospital-
izations and inpatient costs. A significantly lower   proportion 
of adherent patients were hospitalized compared with 
  nonadherent patients. In addition, adherent patients who were 
hospitalized had a significantly shorter length of hospital stay 
and significantly lower hospital costs. Another retrospective 
study used a medical claims database to evaluate the impact 
of adherence with oral aminosalicylate medications in non-
specified gastrointestinal disease. Shaya et al25 demonstrated 
that nonadherent patients incurred higher costs for hospital 
admission, outpatient visits, and office visits. Nonadherent 
patients incurred an additional annual cost of $1875 in total 
health care expenditures; however, medication adherence was 
not measured in that study using the MPR method as used 
in the current study, and the database used in that study was 
limited to enrollees of a private insurance plan in Maryland.
In the Kane et al29 study that evaluated the impact of 
adherence on health care utilization and costs (as measured 
by the number of infusions over one year), nonadherence was 
also associated with significantly greater CD-related medical 
costs (94%) and hospitalization costs (250%) as well as out-
patient costs (68%) when compared with adherent patients. 
Although the Integrated Health Care Information Service 
claims database used in the Kane study is a large database 
covering 25 million managed care lives, it is a smaller and 
less diverse database than the IMS LifeLink Database used 
in the current study. The IMS LifeLink Database includes 
over 90 health plans from across the US and contributes data 
from 60 million covered lives. It is considered a more diverse 
database in terms of health plans and may therefore be more 
nationally representative of this patient population.
The maintenance of remission and prevention of exacerba-
tions that lead to costly hospitalizations and surgeries are the 
main goals in CD treatment. Hospitalizations for CD account 
for approximately half of all direct medical costs (53%–66%), 
and approximately half of all hospitalized patients will 
undergo a surgical procedure.7,31–33 The estimated length of 
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Table 4 Post-index utilization of CD-related health care services
Services Adherent cohort  
(MPR $ 80%),  
n = 344
Nonadherent cohort  
(MPR , 80%),  
n = 104
P value
Pharmacy services
Infliximab
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Immunomodulators
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
5-aminosalicylates
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Corticosteroids
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Other pharmacy services
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
344 (100)
8.06 (0.93)
8
158 (46)
6.87 (3.85)
7
112 (33)
5.26 (3.60)
4
135 (39)
3.02 (2.63)
2
254 (74)
9.08 (6.09)
8
104 (100)
4.99 (1.00)
5
46 (44)
5.80 (3.76)
5
33 (32)
4.45 (2.87)
4
45 (43)
4.07 (3.58)
2
79 (76)
8.25 (6.60)
6
,0.001
0.76
0.08
0.87
0.35
0.46
0.12
0.66
0.10
Outpatient services
Emergency room visits
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Laboratory and pathology
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Radiology
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Physician office visits
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Surgical services
  Patients with at least one claim, n (%)
  Claims
    Mean (SD)
    Median
Ancillary/all other outpatient services
  Patients with at least one claim, n (%)
42 (12)
1.52 (0.83)
1
277 (81)
14.86 (18.10)
10
99 (29)
2.21 (1.66)
2
314 (91)
6.49 (4.77)
6
96 (28)
2.05 (2.02)
1
336 (98)
19 (18)
1.26 (0.56)
1
87 (84)
15.53 (17.97)
11
35 (34)
3.51 (2.64)
3
98 (94)
6.40 (5.87)
5
37 (36)
2.03 (1.46)
1
102 (98)
0.11
0.24
0.47
0.42
0.34
0.004
0.33
0.69
0.13
0.38
0.81
(Continued)
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Table 4 (Continued)
Services Adherent cohort  
(MPR $ 80%),  
n = 344
Nonadherent cohort  
(MPR , 80%),  
n = 104
P value
  Claims
    Mean (SD) 25.38 (14.30) 19.98 (13.91)
    Median 22 18 ,0.001
Abbreviations: CD, Crohn’s disease; MPR, medication possession ratio; SD, standard deviation.
Table 5 Post-index CD-related hospitalizations, lengths of hospital stay, and inpatient costs by cohort
All patients,  
n = 448
Adherent cohort  
(MPR $ 80%),  
n = 344
Nonadherent cohort  
(MPR , 80%),  
n = 104
P value
Hospitalizations among all patients,  
mean (SD)
0.13 (0.40) 0.10 (0.36) 0.21 (0.52)
Hospitalization costs among all patients, 
mean (SD)
$2497 ($12,837) $1235 ($5067) $6673 ($24,631)
Patients with at least one hospitalization,  
n (%)
48 (11) 31 (9) 17 (16) 0.03
  Number of hospitalizations
    Mean (SD)
    Median
1.2 (0.5) 
1
1.2 (0.5) 
1
1.3 (0.5) 
1
 
0.20
  number of hospital days
    Mean (SD)
    Median
8.2 (9.5) 
6
5.5 (3.4) 
5
13.1 (14.2) 
8
 
0.01
  Hospitalization costs, $
    Mean (SD)
    Median
23,308 (32,738) 
15,796
13,704 (10,816) 
9938
40,822 (49,238) 
28,864
 
0.002
Abbreviations: CD, Crohn’s disease; MPR, medication possession ratio; SD, standard deviation.
hospital stay in the US is 8.0 days for nonsurgical treatment 
and 9.6 days for surgical treatment.33 The average cost per hos-
pitalization was $37,459 in the US (2006 adjusted dollars) 
and is rising.7 The cost of hospitalizing patients with CD in 
the US increased from $762 million to $1330 million dollars 
(inflation-adjusted) between 1998 and 2004.34 Most impor-
tantly, the cost of illness in patients with inflammatory bowel 
disease who require hospitalization can be 20 times higher 
than that of ambulatory patients who remain in remission.35 
Therefore, the economic burden that results from not main-
taining remission in patients with CD is substantial. Therapy 
that can limit the need for hospitalization and/or surgery may 
reduce the overall costs of care and improve health-related 
quality of life in patients with CD.
Several clinical trials and retrospective studies have 
shown that scheduled maintenance treatment with inflix-
imab resulted in a significant reduction in the number and 
duration of CD-related hospitalizations, fewer surgeries 
and procedures, fewer developed antibodies, and higher 
rates of mucosal healing compared with episodic treatment 
using infliximab.14–19 A recent retrospective 3-year study 
of 104 patients with CD demonstrated that patients who 
continued an uninterrupted maintenance dosing regimen of 
infliximab had fewer incidences of hospitalization, surgery, 
and disability than patients who had an irregular or inter-
rupted regimen of infliximab prior to initiating a scheduled 
maintenance regimen.37 The data from this study expand the 
findings from previous infliximab studies by demonstrating 
the importance of maintaining adherence with infliximab in 
reducing the costs associated with CD-related hospitaliza-
tions and inpatient costs in a larger sample.
Only a few CD-related health care services in this study 
were impacted over 12 months by nonadherence with 
infliximab. Significant differences in radiology and ancil-
lary outpatient services were noted between adherent and 
nonadherent patients. Given that ancillary services included 
billing for intravenous administration of infliximab, it is not 
surprising that the adherent group with the greater number of 
infusions would also require more ancillary services. These 
data also suggest that nonadherence to infliximab impacts 
utilization of outpatient services to a lesser extent than 
inpatient costs. Although the administrative and pharmacy 
costs of any biologic agent may be higher than oral medica-
tion costs, these data suggest that adherence to maintenance 
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Figure 1 Median Crohn’s disease-related costs of hospitalization among patients 
with Crohn’s disease and with at least one hospitalization.
Note: P = 0.002, adherent versus nonadherent patients.
infliximab is a value-added treatment for CD. The economic 
benefits of adherence to infliximab may be realized in terms 
of reduced hospitalizations, length of hospital stay, and 
inpatient costs. The cost of infliximab administered in the 
inpatient setting was included in the overall inpatient cost 
results. The cost of infliximab administered in the outpatient 
setting was not included. Future analyses may include an 
assessment of the impact of infliximab on total CD-related 
health care resource utilization and costs and not limited only 
to the inpatient setting.
One of the advantages of using an administrative claims 
database to report pharmacoeconomic outcomes is the abil-
ity to examine primary health care data in a real-life setting 
rather than in a highly controlled clinical trial setting. Another 
advantage of the current study design over previous adher-
ence studies is that medians (versus means) are reported. The 
presence of outliers is an inherent flaw in pharmacoeconomic 
cost analyses. Reporting medians in this type of study reduces 
the influence of outliers on the dataset.
The limitations of a claims database are well known 
and include the same biases that occur in any retrospective 
observational study, including inability to determine reasons 
for lack of adherence or discontinuation of drug therapy, lack 
of socioeconomic information, lack of clinical data from 
medical charts that might be associated with health care 
costs, and lack of detailed information on disease activity 
and duration. No statistical adjustments were performed 
when comparing health care utilization and costs between 
the adherent and nonadherent groups because baseline char-
acteristics were mostly similar between cohorts; however, 
similarities in observable characteristics at baseline may not 
always exist in every   adherent and nonadherent CD popula-
tion. It is recommended that statistical adjustments be made 
in any CD population where baseline characteristics differ. 
Unfortunately, no method or mechanism was used in this 
administrative claims database analysis to adjust for unob-
servable characteristics (eg, travel distance to site for inf-
liximab infusion or infliximab supply availability to health 
care professionals) that may have had a role in determining 
the level of observed adherence.   Information regarding the 
dose of infliximab given at each infusion was not available, so 
while the infusion patterns were consistent with prescribing 
recommendations, the actual dose was unknown. Finally, this 
database contained information largely from commercial pay-
ers in the US; therefore, the results may not be generalizable 
to patients covered by Medicare or Medicaid or to patients 
outside the US.
Conclusion
In this study, adherence with maintenance infliximab over 
12 months was associated with a lower rate of CD-related 
hospitalizations. Furthermore, among those who were hos-
pitalized, adherence had an observed beneficial economic 
impact, as evidenced by lower CD-related inpatient costs 
and a shorter length of hospital stay. Additional compara-
tive studies are needed to compare adherence with more 
frequently versus less frequently administered therapies for 
the treatment of CD and their resulting effects on clinical 
and health economic outcomes.
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